The PDZK1 antibody is a crucial tool for studying the PDZ domain-containing protein 1 (PDZK1), a scaffold protein involved in regulating membrane protein trafficking, signal transduction, and cellular homeostasis. PDZK1. also known as NHERF3 or CAP70. contains four PDZ domains that mediate protein-protein interactions by binding to C-terminal motifs of target proteins. It plays a vital role in organizing multi-protein complexes at the plasma membrane, particularly in epithelial cells of the kidneys, intestines, and liver. PDZK1 interacts with transporters (e.g., SLC9A3R1. CFTR), receptors, and ion channels, influencing nutrient absorption, pH regulation, and drug metabolism. Dysregulation of PDZK1 is linked to metabolic disorders, hypertension, and cancers, where it may modulate pathways like MAPK/ERK or PI3K/AKT.
PDZK1 antibodies, typically developed in rabbit or mouse hosts, enable the detection and localization of PDZK1 in techniques such as Western blotting (detecting ~70 kDa protein), immunohistochemistry, and immunofluorescence. These antibodies aid in exploring PDZK1's tissue-specific expression, post-translational modifications, and interactions with signaling partners. Researchers rely on validated PDZK1 antibodies to investigate its roles in disease mechanisms or therapeutic targeting. Specificity and batch variability require careful validation using knockout controls or epitope mapping to ensure accurate experimental outcomes.